ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CL1991B |
|
2805804-54-8 |
CP-547632 TFA 98+% |
C20H24BrF2N5O3S·C2HF3O2 | |
CL2879A |
|
210644-62-5 |
(Z)-Orantinib | (Z)-SU6668 | (Z)-TSU-68 98+% |
C18H18N2O3 | |
CL2509 |
|
1013920-15-4 |
Vorolanib (X-82,CM082) 98+% |
C23H26FN5O3 | |
CL2507A |
|
1218779-75-9 |
Apatinib Mesylate 98+% |
C24H23N5O · CH4O3S | |
CL2507 |
|
811803-05-1 |
Apatinib | Apatinib Free base | YN968D1| Rivoceranib 98+% |
C24H23N5O | |
CL2424 |
|
557795-19-4 |
Sunitinib | Sunitinib Base 99+% |
C22H27FN4O2 | |
CLA1339 |
|
1350624-75-7 |
Margetuximab (Anti-ERBB2 / HER2 / CD340) 95+% |
— | |
CLA1267 |
|
1024603-92-6 |
Icrucumab (Anti-VEGFR1 / FLT1) 95+% |
— | |
CLA1179 |
|
934216-54-3 |
Alacizumab (Anti-VEGFR2 / KDR / CD309) 95+% |
— | |
CL2214 |
|
215543-92-3 |
(Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid. 98+% |
C17H16N2O3 | |
CLA1033 |
|
1018448-65-1 |
Ado-trastuzumab Emtansine (TDM-1) 95+% |
— | |
CL1633 |
|
417716-92-8 |
Lenvatinib | E7080 98+% |
C21H19ClN4O4 | |
CL1637 |
|
319460-85-0 |
Axitinib (AG-013736) 98+% |
C22H18N4OS | |
CL1033 |
|
808118-40-3 |
Roxadustat (FG-4592) 98+% |
C19H16N2O5 | |
CLA1025 |
|
380610-27-5 |
Pertuzumab; 2C4 98+% |
— | |
CLA1018 |
|
947687-13-0 |
Ramucirumab; LY3009806; IMC-1121B 98+% |
— | |
CLA1008 |
|
216974-75-3 |
Bevacizumab (anti-VEGF) ; rhuMab VEGF 95+% |
— | |
CL1991 |
|
252003-65-9 |
CP-547632 | PAN-90806 | CP-632 | OSI-632 98+% |
C20H24BrF2N5O3S | |
CL1906 |
|
212141-51-0 |
Vatalanib Dihydrochloride; Vatalanib 2HCl 98+% |
C20H17Cl3N4 | |
HL1306 |
|
568-72-9 |
Tanshinone IIA | Dan Shen Ketone 98+% |
C19H18O3 | |